DCI Group on behalf of Definium
DCI Group on behalf of Definium
About
Definium Therapeutics, formerly known as MindMed, is a clinical-stage biopharmaceutical company focused on developing innovative psychedelic-based medicines for psychiatric and neurological disorders. The company specializes in treatments for generalized anxiety disorder, major depressive disorder, PTSD, and other brain health conditions. Its research pipeline includes DT120, an LSD-based investigational therapy, and DT402, an MDMA-derived drug candidate. Definium aims to transform mental healthcare through scientific research, clinical trials, and the development of accessible, effective treatments.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – biotechnology and diagnostic companies, medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.